Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Larimar Therapeutics, Inc. (LRMR) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Larimar Therapeutics, Inc. (LRMR) - free report >>
Image: Bigstock
New Strong Buy Stocks for April 12th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Celularity Inc. (CELU - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
Celularity, Inc. Price and Consensus
Celularity, Inc. price-consensus-chart | Celularity, Inc. Quote
MoneyGram International, Inc. : This peer-to-peer payments and money transfer services company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
MoneyGram International Inc. Price and Consensus
MoneyGram International Inc. price-consensus-chart | MoneyGram International Inc. Quote
Larimar Therapeutics, Inc. (LRMR - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 47.8% over the last 60 days.
Larimar Therapeutics, Inc. Price and Consensus
Larimar Therapeutics, Inc. price-consensus-chart | Larimar Therapeutics, Inc. Quote
EQRx, Inc. : This medicine company focused on oncology and immune-inflammatory diseases has seen the Zacks Consensus Estimate for its current year earnings increasing 12.1% over the last 60 days.
EQRx, Inc. Price and Consensus
EQRx, Inc. price-consensus-chart | EQRx, Inc. Quote
Surrozen, Inc. (SRZN - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its next year earnings increasing 15.3% over the last 60 days.
Surrozen, Inc. Price and Consensus
Surrozen, Inc. price-consensus-chart | Surrozen, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.